SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

RPG Life Sciences Ltd (RPGLIFE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532983 NSE: RPGLIFE Pharmaceuticals & Drugs | Small Cap | RPG Life Sciences Share Price

₹2,164 13.80 (0.64%)

As on 05-Jun'26 16:59

RPG Life Sciences Ltd (RPGLIFE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532983 NSE: RPGLIFE Pharmaceuticals & Drugs | Small Cap | RPG Life Sciences Share Price

₹2,164 13.80 (0.64%)

As on 05-Jun'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹3,556 Cr.
Current Price
₹2,164
52-Week Low / High
₹1,731 / 2,716
TTM EPS
₹69.6
TTM Sales
₹708 Cr.
Book Value per Share
₹366
P/E Ratio
30.88
Higher than its 5-year historical median
Industry PE
46.5
Price to Book (P/B)
5.87
In line with its 5-year historical median
Price to Sales (P/S)
5.03
Higher than its 5-year historical median
EV/EBITDA
19.80
Higher than its 5-year historical median
Dividend Yield
1.05%
Profitability Efficiency
Return on Equity (ROE)
40.48%
Outperforms industry median
Return on Capital Employed (ROCE)
51.79%
Outperforms industry median
Return on Assets (ROA)
31.35%
Operating Profit Margin
24.3%
Net Profit Margin
28.04%
Gross Profit Margin
24.5%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
12.26%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
23.1%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
109.03%
Asset Quality
Promoter Holding
72.95%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹592 Cr.
Equity
₹13.2 Cr.
Face Value
₹8
All Time Low / High
₹17.10 / 2976.70

RPG Life Sciences stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Overvalued

Price Trend

Semi Strong
Q.1 Is RPG Life Sciences Ltd a good quality company?
RPG Life Sciences Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does RPG Life Sciences Ltd performance compare with that of its Peers?
Q.1 Revenue growth of RPG Life Sciences Ltd vs industry peers?
RPG Life Sciences Ltd revenue CAGR is 11.71%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of RPG Life Sciences Ltd?
Promoters hold 72.95% of the RPG Life Sciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of RPG Life Sciences Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 24.7% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
RPG Life Sciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 9%10.5%12.5%9.8%20.4%27.3%31.5%32.9%35%51.8%-
Value Creation
Index
-0.4-0.3-0.1-0.30.51.01.31.41.52.7-

Growth Parameters

Sales 279294344330376389440513582653708
Sales YoY Gr.-5.1%17.1%-4%13.8%3.6%13.1%16.5%13.5%12.3%-
Adj EPS 6.77.486.319.62430.8415375.369.6
YoY Gr.-9.7%9%-21.7%212.4%22.2%28.5%33%29.3%42%-
BVPS (₹) 80.888.993.697.1106.8130.9154.7186226.7320.8366
Adj Net
Profit
11.112.213.310.432.539.75167.887.7124115
Cash Flow from Ops. 32.87.314.745.850.258.364.890.894.477.9-
Debt/CF from Ops. 0.76.13.70.80.200000-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales 9.9%11.7%14.1%12.3%
Adj EPS 30.8%30.9%34.7%42%
BVPS16.6%24.6%27.5%41.5%
Share Price 24.2% 37.6% 39.5% 1.1%

Key Financial Parameters

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
8.68.78.86.619.320.221.624.125.727.520.3
Op. Profit
Mgn %
89.810.810.51618.219.820.322.224.320.8
Net Profit
Mgn %
44.13.93.28.610.211.613.215.119.116.3
Debt to
Equity
0.20.30.40.20.1000000
Working Cap
Days
137123113122105118105979698127
Cash Conv.
Cycle
4849444440444030232689

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales279294344330376389440513582653
Operating Expenses + 257265307296316318353409453494
Manufacturing Costs38303229334051505864
Material Costs8596107104120121128157168197
Employee Cost 747690909195100117132126
Other Costs 606478737262758595108
Operating Profit 22293734607187104129159
Operating Profit Margin (%) 8.0%9.8%10.8%10.4%15.9%18.2%19.8%20.2%22.2%24.3%
Other Income + 21211135714
Exceptional Items 0000-5000083
Interest 2455321112
Depreciation 10111415161616161721
Profit Before Tax 1215201536547392118233
Tax 027471422243050
Profit After Tax 121213112940516888183
PAT Margin (%) 4.2%4.1%3.9%3.3%7.7%10.3%11.7%13.2%15.1%28.0%
Adjusted EPS (₹)7.07.38.16.517.524.231.140.953.0110.8
Dividend Payout Ratio (%)22.80%38.30%29.50%36.70%22.80%29.80%30.80%29.30%30.20%21.70%

Valuation of RPG Life Sciences - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 134147155161177216256308375531
Share Capital 13131313131313131313
Reserves 120134142147163203243294362517
Debt +22404836711000
Long Term Debt016107210000
Short Term Debt22243829510000
Minority Interest0000000000
Trade Payables34295225444746657179
Others Liabilities 33212927403843476647
Total Liabilities 223236284248268303345419512657

Fixed Assets

Net Fixed Assets +109137131128123113104124114172
Gross Block190142151163174180186220222276
Accumulated Depreciation816203551678396108104
CWIP 22917101231259616
Investments 00000005891127
Inventories394654414758839510193
Trade Receivables37396839635733374987
Cash Equivalents 1211141705736140
Others Assets 35112222242224222523
Total Assets 223236284248268303345419512657

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 3371546505865919478
PBT 1223201536547392118233
Adjustment 13717202317141313-76
Changes in Working Capital 11-19-1914-2-4-311-7-26
Tax Paid -2-4-4-4-6-8-19-25-29-53
Cash Flow From Investing Activity + -15-30-16-19-11-8-35-106-79-42
Capex -15-55-15-20-11-8-24-33-6973
Net Investments -0-0-0000-12-57-27-29
Others 02500011-1617-86
Cash Flow From Financing Activity + -18230-27-39-10-14-17-20-27
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -020-4-9-0-4-0-0-00
Interest Paid -2-3-4-4-2-1-1-0-0-1
Dividend Paid -40-6-5-130-12-16-20-26
Others -11614-9-25-5-1-100
Net Cash Flow -01-1004017-32-59

Financial Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)8.988.628.916.8617.2120.3621.824.0125.6940.48
ROCE (%)8.9710.4512.529.8120.3527.2731.4632.9234.9651.79
Asset Turnover Ratio1.331.341.481.391.591.471.481.451.341.2
PAT to CFO Conversion(x)2.750.581.154.181.721.451.271.341.070.43
Working Capital Days
Receivable Days48.8045.4050.905345.4052.5034.4023.2025.3035.40
Inventory Days46.2050.4047.1046.9038.9045.6053.8058.6057.4050.50
Payable Days126.80118.50137.50135.20106.10138.20132.90128.40147.60139.60

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

RPG Life Sciences Ltd FAQs

The current trading price of RPG Life Sciences on 05-Jun-2026 16:59 is ₹2,164.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Jun-2026 the market cap of RPG Life Sciences stood at ₹3,556.2 Cr

The latest P/E ratio of RPG Life Sciences as of 04-Jun-2026 is 30.88.

The latest P/B ratio of RPG Life Sciences as of 04-Jun-2026 is 5.87.

The 52-week high of RPG Life Sciences is ₹2,715.9 and the 52-week low is ₹1,731.3.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of RPG Life Sciences is ₹708 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that RPG Life Sciences Ltd is a good quality company.

The key valuation ratios of RPG Life Sciences Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of RPG Life Sciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About RPG Life Sciences Ltd

RPG Life Sciences (RPGLS) is a pharmaceutical organization and was formerly known as Searle (India) Limited. It is a full spectrum world class, customer focussed, innovative pharmaceutical organisation. RPGLS started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to the RPG Group. The company’s name was changed to RPG Life Sciences Ltd effective April 1, 1999.This company belongs to RPG group

RPGLS was in the business of pharmaceuticals and agrochemicals. It divested the agrochemicals business in the year 2001, as per the strategic decision to focus on pharmaceuticals, fermentation and biotechnology. It develops, manufactures and markets, for national and international markets, a broad range of branded formulations, generics and bulk drugs developed through fermentation and chemical synthesis routes. RPG Life Sciences has research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. Each of these areas have their respective manufacturing facilities RPGLS employs 750 people. It is a multi-location pharmaceutical manufacturing company with four locations. The manufacturing unit at Thane produces Active Pharmaceuticals Ingredients (also called as bulk drugs) and is ISO 9001 certified and has Therapeutic Goods Administration (TGA), Australia, and approval for three of its major products namely Diphenoxylate Hydrochloride, Haloperidol and Propanthelene Bromide.

The Formulation Plant at Ankleshwar GIDC is ISO 9002 and ISO14001 certified and manufactures pharmaceuticals formulations for domestic as well as for exports. The site also has MHRA (Medicines and Healthcare products Regulatory Agency, UK) approved plant for catering to its global generic business. The second plant at Ankleshwar makes API through the fermentation route to cater to the biotech business.

RPGLS is present in the domestic as well as the international markets. It exports its products primarily to Europe, Latin America, Africa, Australia, CIS Nations and South East Asia.

Major Activities of the Company:

  • Manufacturing and marketing of bulk drugs (synthetic Active Pharmaceutical Ingredients) & formulations internationally [SBU- I],
  • Pharmaceutical formulations & domestic marketing [SBU – II] and Fermentation & biotechnology [SBU – III].

Company’s Patnership:

It is represented in over thirty countries through strategic partnerships and joint ventures.

  • Dossiers/DMF Europe, Canada
  • Artificial Sweetner-UK
  • NSAID-Europe
  •  Formulations - Asia, Canada, Europe.

Achievements:

  • 8 processes patented granted,both in India and overseas
  • First to manufacture Cyclosporin, Daunarubicin, doxorubican and epirubicin in India
  • One of the two manufacturers of Vitamin B12 in India
  • R&D approved  by Department of Science & Technology, Government of India.
  • Only manufacturer of Spironolactone, by the fermentation route, in India.
  • Marketing APIs and formulations catering to all key therapeutic areas across the world.
You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×